We are working to restore the Unionpedia app on the Google Play Store
OutgoingIncoming
🌟We've simplified our design for better navigation!
Instagram Facebook X LinkedIn

Ponezumab

Index Ponezumab

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease. [1]

Table of Contents

  1. 4 relations: Alzheimer's disease, American Medical Association, Amyloid beta, Pfizer.

  2. Anti-amyloid monoclonal antibodies
  3. Experimental monoclonal antibodies

Alzheimer's disease

Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, and is the cause of 60–70% of cases of dementia.

See Ponezumab and Alzheimer's disease

American Medical Association

The American Medical Association (AMA) is an American professional association and lobbying group of physicians and medical students.

See Ponezumab and American Medical Association

Amyloid beta

Amyloid beta (Aβ or Abeta) denotes peptides of 36–43 amino acids that are the main component of the amyloid plaques found in the brains of people with Alzheimer's disease.

See Ponezumab and Amyloid beta

Pfizer

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City.

See Ponezumab and Pfizer

See also

Anti-amyloid monoclonal antibodies

Experimental monoclonal antibodies

References

[1] https://en.wikipedia.org/wiki/Ponezumab